May 11, 2020 / 11:36 AM / 19 days ago

BRIEF-Kiniksa Reports Data For Mavrilimumab In Covid-19 Pneumonia And Hyperinflammation And For Vixarelimab In Diseases Characterized By Chronic Pruritus

May 11 (Reuters) - Kiniksa Pharmaceuticals Ltd:

* KINIKSA REPORTS DATA FOR MAVRILIMUMAB IN COVID-19 PNEUMONIA AND HYPERINFLAMMATION AND FOR VIXARELIMAB IN DISEASES CHARACTERIZED BY CHRONIC PRURITUS

* KINIKSA - PLAQUE PSORIASIS COHORT ACHIEVED STATISTICALLY SIGNIFICANT REDUCTION IN WEEKLY-AVERAGE WORST-ITCH NUMERIC RATING SCALE (WI-NRS) AT WEEK 8

* KINIKSA - VIXARELIMAB EXPLORATORY PHASE 2 TRIAL IN DISEASES CHARACTERIZED BY CHRONIC PRURITUS SHOWED ENCOURAGING EFFICACY RESULTS IN 4 OUT OF 5 COHORTS

* KINIKSA - MAVRILIMUMAB TREATMENT PROTOCOL IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA AND HYPERINFLAMMATION SHOWED IMPROVED CLINICAL OUTCOMES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below